Response to an Intervention With Omega-3 (RIO

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-30

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The RIO-Study project is a randomized, controlled, double-blind, crossover trial aimed at determining the effectiveness of omega-3 fatty acids at nutritional doses on lipid metabolism and inflammation in overweight and obese individuals with hypertriglyceridemia in Chile.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Omega-3 Fatty Acids on Fasting and Postprandial Triglycerides (TG) Response - a Pilot Study

NCT05621083

Healthy

COMPLETED NA

Transcriptomics of Mononuclear Cells and Inflammatory Status of Obese Patients Treated With Omega-3 Fatty Acids

NCT05219890

Obesity Inflammation Immune System Disorder

WITHDRAWN NA

Gestational Obesity and Interventions With Probiotics or Fish Oil Trial

NCT03215784

Obesity Pregnancy Inflammation

UNKNOWN NA

Health Benefits of Functional Oil (Mega 3 Fatty Acids From Fish Oil) on Obese People

NCT01739998

Obesity

COMPLETED PHASE4

Window of Opportunity Study Targeting the Inflammatory Milieu

NCT01881048

Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer +4 more

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will include 40 participants (each participant will serve as their own control) aged 18-65, with 25-34.9 kg/m2 BMI and fasting triglycerides (TG) of 100-215 mg/dL. The intervention consists of 250 mg EPA from algae oil versus high oleic sunflower oil (HOSO) for 6 weeks each, after a 10-week washout period, the treatments will be switched for another 6 weeks, considering four visits during the whole study. The main outcomes to be evaluated are serum triglyceride levels, expression of target genes in peripheral blood mononuclear cells (PBMCs), low-grade inflammation biomarkers, and very low-density lipoprotein (VLDL) atherogenic properties. The study also analyzes background diet, chrononutrition, and physical activity aspects. Results are expected to provide new insights into the effects of nutritional doses of omega-3 in the Chilean population, particularly on fasting and postprandial triglyceride metabolism and cardiovascular disease risk reduction.

Before and after each intervention period, fasting blood samples will be collected. On each visit day, participants will consume a standardized breakfast (three slices of white bread with butter and jam), and postprandial blood samples will be taken at 0, 2, 4, and 6 hours to measure triglycerides and other lipid parameters.

The study will assess:

1. Serum triglyceride levels in fasting and postprandial states
2. Expression of target genes Peroxisome proliferator-activated receptor alpha (PPARα) and Sterol regulatory element binding protein-1 (SREBP1c) in peripheral blood mononuclear cells (PBMCs) at fasting (0h) and postprandial (4h) states
3. Levels of low-grade inflammation biomarkers Tumor Necrosis Factor-Alpha (TNFα) and Interleukin 6 ( IL-6) at fasting (0h) and postprandial (4h) states
4. Very low-density lipoprotein (VLDL) atherogenic properties in the fasting state Additionally, the investigators will collect data on chrononutrition, physical activity, and energy drink intake to understand their impact on lipid metabolism. Anthropometric measurements and bioimpedance analysis will be performed at each visit.

The study will collaborate with international partners for specialized analyses, including gene expression studies and VLDL atherogenic properties assessment.

This comprehensive approach aims to provide new insights into the effects of nutritional doses of omega-3 fatty acids on lipid metabolism and inflammation in the Chilean population, with a particular focus on postprandial triglyceride metabolism and cardiovascular disease risk reduction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Hypertriglyceridemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, controlled, double - blind, crossover study.

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

The principal investigator will have exclusive access to the randomization code, which specifies the order of administration (either starting with HOSO or omega-3). This code is generated by an external statistician. The PI will ensure that the identical boxes containing capsules (both HOSO and Omega-3) are marked only with an Identification (ID). The randomization code will remain unknown to the participant, care provider, and outcomes assessor until after the primary outcome data has been analyzed.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Marine Omega-3 fatty acid supplement

Participants will be randomized to either star to receive a capsule/day with omega-3 fatty acid from 1g Nannochloropsis sp. microalga (250 mg of EPA) for 6 weeks. Followed by a wash-out period of 10 weeks.

Group Type EXPERIMENTAL

Omega-3

Intervention Type DIETARY_SUPPLEMENT

Dietary Supplement: Omega-3 In the marine Omega-3 fatty acid period, the participants will receive a capsule with 250 mg of EPA per day during 6 weeks.

High-oleic sunflower oil (HOSO) containing no EPA or other omega-3 fatty acid

Participants will be randomized to either star to receive a placebo capsule/day with the same weight of high oleic sunflower oil -HOSO (with no EPA or other omega-3 fatty acid content), for 6 weeks. Followed by a wash-out period of 10 weeks.

Group Type PLACEBO_COMPARATOR

HOSO

Intervention Type DIETARY_SUPPLEMENT

Dietary Supplement: HOSO In the HOSO period, the participants will receive a capsule with the similar weight of HOSO per day during 6 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3

Dietary Supplement: Omega-3 In the marine Omega-3 fatty acid period, the participants will receive a capsule with 250 mg of EPA per day during 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

HOSO

Dietary Supplement: HOSO In the HOSO period, the participants will receive a capsule with the similar weight of HOSO per day during 6 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults between 18 and 65 years old, male and female.
* Body mass index (BMI) between 25 - 34,9 kg/m2.
* Fasting triglycerides between 100-215 mg/dL (1.13-2.43 mmol/L).

Exclusion Criteria

* Unable to give informed consent.
* If you consume Omega-3 (you must stop consumption at least 10 weeks prior).
* Normal or Obesity Nutritional Status. Large weight variation (\>10%) in the last 3 months.
* Triglycerides \> 215 mg/dL.
* Blood pressure \> 140/90 mmHg.
* Uncontrolled metabolic and chronic diseases (reference parameters for the disease in question will be considered).
* Pregnant women or those who are breastfeeding.
* Allergy or intolerance to gluten, milk protein and/or lactose, or any ingredient in the capsules (omega-3, oleic acid oil).
* Use of medications that affect lipid metabolism: Fibrates. (Statins will be allowed only if the treatment has been ongoing for over 3 months).
* Blood donation two months before or during the study period.
* Excessive alcohol consumption (\>3 cans of beer per day)
* Taking anticoagulants.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes